Scheme 2. Initial Study on Rh-Catalyzed Formal Cycloaddi-
tions with Chiral Sulfur/Alkene Ligands
Scheme 1. Rh-Catalyzed Stereospecific Reaction of Butadiene
Monoxide with Imines5
been working on the development of novel chiral olefin
ligands,8ꢀ10 and in some cases, this type of ligand shows
higher activity and selectivity than many other types
of ligand. Because of this, we envisioned that the
Rh-catalyzed asymmetric reaction of racemic butadiene
monoxide (2) with imines could probably be achieved
using chiral olefin ligands. Herein, we report our efforts
in this area.
Initially, we selected the novel reaction of isatin imine 4a
with 1.2 equivalent of racemic butadiene monoxide (2)
which would produce spirooxindole oxazolidines.11,12 This
would serve as the model reaction to test our hypothesis on
(7) For recent reviews on oxazolidine, see: (a) Scott, J. D.; William,
R. M. Chem. Rev. 2002, 102, 1669. (b) Royer, J.; Bonin, M.; Micouin, L.
Chem. Rev. 2004, 104, 2311. (c) Wu, G.; Huang, M. Chem. Rev. 2006,
106, 2596.
Table 1. Optimization of Reaction Conditionsa
(8) For leading reviews on chiral alkene ligands, see: (a) Glorius, F.
Angew. Chem., Int. Ed. 2004, 43, 3364. (b) Johnson, J. B.; Rovis, T.
(()-2
€
Angew. Chem., Int. Ed. 2008, 47, 840. (c) Defieber, C.; Grutzmacher, H.;
entry (equiv) AgX solvent time (h) convb (%) drb eec (%)
Carreira, E. M. Angew. Chem., Int. Ed. 2008, 47, 4482. (d) Shintani, R.;
Hayashi, T. Aldrichimica Acta 2009, 42, 31. (e) Tian, P.; Dong, H.-Q.;
Lin, G.-Q. ACS catal 2012, 2, 95.
1
1.2
1.2
1.2
1.2
1.2
1.2
2.0
2.0
AgOTf acetone
AgBF4 acetone
AgPF6 acetone
AgSbF6 acetone
AgOTf EtOAc
AgOTf EtOAc
AgOTf EtOAc
AgOTf EtOAc
1
84
90
80
99
74
83
99
99
99
99
86
50:1
20:1
50:1
20:1
10:1
10:1
10:1
10:1
12:1
20:1
20:1
68
56
60
42
84
65
84
88
94
95
95
2
1
(9) For leading references on chiral alkene ligands, see: (a) Hayashi,
T.; Ueyama, K.; Tokunaga, N.; Yoshida, K. J. Am. Chem. Soc. 2003,
125, 11508. (b) Fischer, C.; Defieber, C.; Suzuki, T.; Carreira, E. M.
J. Am. Chem. Soc. 2004, 126, 1628. (c) Wang, Z.-Q.; Feng, C.-G.; Xu,
M.-H.; Lin, G.-Q. J. Am. Chem. Soc. 2007, 129, 5336. (d) Gendrineau,
T.; Chuzel, O.; Eijsberg, H.; Genet, J.-P.; Darses, S. Angew. Chem., Int.
Ed. 2008, 47, 7669. (e) Luo, Y.; Carnell, A. J. Angew. Chem., Int. Ed.
2010, 49, 2750. (f) Pattison, G.; Piraux, G.; Lam, H. W. J. Am. Chem.
Soc. 2010, 132, 14373. (g) Maire, P.; Deblon, S.; Breher, F.; Geier, J.;
3
1
4
1
5
2.5
6
12
7
1
8d
9d
10d
11e
2.5
2.5
2.5
3.0 AgOTf EtOAc
€
€
€
€
Bohler, C.; Ruegger, H.; Schonberg, H.; Grutzmacher, H. Chem.;Eur.
J. 2004, 10, 4198. (h) Shintani, R.; Duan, W.-L.; Nagano, T.; Okada, A.;
Hayashi, T. Angew. Chem., Int. Ed. 2005, 44, 4611. (i) Defieber, C.;
Ariger, M. A.; Moriel, P.; Carreira, E. M. Angew. Chem., Int. Ed. 2007,
4.0
3.0
AgOTf EtOAc
AgOTf EtOAc
12
a All of the reactions were carried out with 4a (0.20 mmol), (()-2 as
indicated, [Rh(C2H4)2Cl]2 (0.005 mmol), ligand 6f (0.012 mmol), and
AgX (0.012 mmol) in solvent (1.0 mL) at 20 °C unless other noted. b The
conversion and dr were determined by crude 1H NMR. c The ee was
determined by chiral HPLC (Chiralcel OD-H column). d 3 mol %
catalyst was used. e 1 mol % catalyst was used.
€
€
46, 3139. (j) Maire, P.; Breher, F.; Schonberg, H.; Grutzmacher, H.
€
Organometallics 2005, 24, 3207. (k) Hahn, B. T.; Tewes, F.; Frohlich, R.;
Glorius, F. Angew. Chem., Int. Ed. 2010, 49, 1143.
(10) For examples on alkene ligands developed by our group, see the
following. Acyclic diene: (a) Hu, X.; Zhuang, M.; Cao, Z.; Du, H. Org.
Lett. 2009, 11, 4744. P/alkene: (b) Liu, Z.; Du, H. Org. Lett. 2010, 12,
3054. S/alkene: (c) Feng, X.; Wang, Y.; Wei, B.; Yang, J.; Du, H. Org.
Lett. 2011, 13, 3300. (d) Feng, X.; Wei, B.; Yang, J.; Du, H. Org. Biomol.
Chem. 2011, 9, 5927. (e) Wang, Y.; Feng, X.; Du, H. Org. Lett. 2011, 13,
4954. (f) Feng, X.; Nie, Y.; Yang, J.; Du, H. Org. Lett. 2012, 14, 624.
(11) For recent reviews on spriooxindoles, see: (a) Marti, C.;
Carreira, E. M. Eur. J. Org. Chem. 2003, 2209. (b) Williams, R. M.;
Cox, R. J. Acc. Chem. Res. 2003, 36, 127. (c) Galliord, C. V.; Scheidt,
K. A. Angew. Chem., Int. Ed. 2007, 47, 8748. (d) Trost, B. M.; Brennan,
M. K. Synthesis 2009, 3003.
(12) For examples on spriooxindole oxazolidines, see: (a) Risitano,
F.; Grassi, G.; Foti, F.; Bruno, G.; Rotondo, A. Heterocycles 2003, 60,
857. (b) Badillo, J. J.; Arevalo, G. E.; Fettinger, J. C.; Franz, A. K. Org.
Lett. 2011, 13, 418.
(13) For examples on S/alkene hybrid ligands developed by other
groups, see: (a) Thaler, T.; Guo, L.-N.; Steib, A. K.; Raducan, M.;
Karaghiosoff, K.; Mayer, P.; Knochel, P. Org. Lett. 2011, 13, 3182. (b)
Jin, S.-S.; Wang, H.; Xu, M.-H. Chem. Commun. 2011, 47, 7230. (c) Qi,
W.-Y.; Zhu, T.-S.; Xu, M.-H. Org. Lett. 2011, 13, 3410. (d) Chen, G.;
Gui, J.; Li, L.; Liao, J. Angew. Chem., Int. Ed. 2011, 50, 7681. (e) Xue, F.;
Li, X.; Wan, B. J. Org. Chem. 2011, 76, 7256. (f) Zhu, T.-S.; Jin, S.-S.;
Xu, M.-H. Angew. Chem., Int. Ed. 2012, 51, 780.
the utility of chiral alkene ligands for allylrhodium trans-
formations. As shown in Scheme 2, a variety of easily
accessible chiral sulfur/alkene ligands10e,f,13 were found to
be effective for this reaction to afford optically active
spirooxindole oxazolidines 5a with up to 68% ee and high
diastereoselectivity, which indicated that the stereochem-
istry of this reaction is at least partially controlled by chiral
rhodium catalysts.
To further improve the enantioselectivity, various con-
ditions for the Rh-catalyzed reaction between 4a and (()-
2, with the use of ligand 6f, were thoroughly examined, and
some results are summarized in Table 1. Studies on the
influence of the counteranion on Rh center showed that
Org. Lett., Vol. 14, No. 12, 2012
3155